• Perrigo, a major holding in the Invesco High Yield Dividend ETF (PEY), has recently come under scrutiny as it pays out more in dividends than it earns, reflecting pressures from weaker business performance.
• This mismatch between earnings and dividends raises a material question for income-focused investors: how reliable is Perrigo’s payout policy over time?
• We’ll now examine how concerns about Perrigo’s dividend sustainability shape its broader investment narrative for current and prospective shareholders.

These 9 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

What Is Perrigo's Investment Narrative?

For Perrigo to make sense in a portfolio, you need to be comfortable with a value story built around a low sales multiple, a relatively new management team trying to reshape the business, and the long-term role of store-brand OTC products in consumer healthcare. The recent spotlight on Perrigo paying out more in dividends than it earns tightens the focus on the main short term catalysts: the strategic review of the infant formula unit, progress on leverage reduction, and any reset of dividend policy. With guidance already lowered and a class action challenging past disclosures around formula investments, the dividend strain looks more like a symptom than an isolated issue. Given the share price’s steep multi‑year decline, the key question now is whether management prioritizes balance sheet repair over maintaining the current payout.

However, investors also need to understand how a stressed dividend can limit future flexibility. Despite retreating, Perrigo's shares might still be trading above their fair value and there could be some more downside. Discover how much.

Exploring Other Perspectives

Five Simply Wall St Community fair value views span roughly US$21 to just over US$72, underscoring how far apart expectations sit. Set that against today’s concerns about dividend coverage and legal uncertainty, and you can see why opinions on Perrigo’s future operating performance diverge so sharply.

Explore 5 other fair value estimates on Perrigo - why the stock might be worth just $21.00!

Build Your Own Perrigo Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Perrigo research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Perrigo research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Perrigo's overall financial health at a glance.

Looking For Alternative Opportunities?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• AI is about to change healthcare. These 109 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• We've found 13 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• This technology could replace computers: discover 23 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.